NC
KURA icon

nVerses Capital’s Kura Oncology KURA Stock Holding History

nVerses Capital’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Buy
+26,023
New +$246K 0.44% 65
2024
Q4 		– Sell
-1,300
Closed -$25.4K – 460
2024
Q3 		$25.4K Buy
+1,300
New +$26.3K 0.01% 768

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

nVerses Capital's KURA Position: Q2 2026 in Review

nVerses Capital opened a new position in Kura Oncology (KURA) in Q2 2026: 26,023 shares worth $285K. The stake represents 0.44% of the portfolio and ranks #65 among its holdings. This is a return to the name: nVerses Capital previously reported a position in KURA as recently as Q3 2024.

nVerses Capital first reported a position in KURA in Q3 2024 and has held it in 2 quarters since. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • nVerses Capital held 26,023 shares of Kura Oncology worth $285K as of Q2 2026.
  • Kura Oncology was a new nVerses Capital position in Q2 2026.
  • Kura Oncology made up 0.44% of nVerses Capital's portfolio in Q2 2026, its #65 holding.
  • nVerses Capital first reported a position in Kura Oncology in Q3 2024 and has held it in 2 quarters since.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.